breast cancer
-
【Asset for Licensing】Novel LIV-1-targeted ADC armed with optimized TOPO1 inhibitor payload
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
【Asset for Licensing】Orally bioavailable selective PI3Kα small-molecule inhibitor
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
【Asset for Licensing】Orally available selective KAT6A/B small molecule inhibitor
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
【Asset for Licensing】Potent and selective oral PARP1 small-molecule inhibitor
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
【Product Wanted】HER2 Small Molecules That Can Penetrate BBB
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
-
ANTI-CDCP1 mAb and ADC 【Product for Licensing】
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. We will discuss with you and may present the non-confidential deck to you for review asap.
-
ASCO Express: From “low expression” to “even lower expression”, the best-selling ADC enters the next level!
Following the FDA’s accelerated approval of Enhertu (trastuzumab deruxtecan, …
